Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Does the Forecast Indicate for the Tofacitinib Market From 2025 to 2029?

In the past few years, the tofacitinib market has experienced a significant surge. The market value will climb from $3.08 billion in 2024 to $3.42 billion in 2025, with a compound annual growth rate (CAGR) of 10.9%. Factors such as clinical efficiency and trials, regulatory concessions, an increased prevalence of specific conditions, the prescribing habits of doctors, and patient approval, have all played a part in the historical period’s growth.

In the coming years, the tofacitinib market is predicted to undergo speedy expansion. By 2029, the market could reach up to $5.67 billion, reflecting a compound annual growth rate (CAGR) of 13.5%. Factors contributing to the projected growth in the forecast period are broader indications, market access strategies, a competitive environment, real-world evidence, and a focus on patient-centric healthcare. The forecast period is expected to see key trends such as heightened attention to pediatric rheumatoid arthritis treatment, the investigation of tofacitinib usage in dermatological conditions, strategic alliances and partnerships, the addition of real-world evidence in treatment protocols, and an emphasis on individualized treatment methodologies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10779&type=smp

What Elements Are Contributing To Growth In The Tofacitinib Market?

The escalation in the occurrence of rheumatoid arthritis is projected to fuel the development of the tofacitinib market in the near future. An autoimmune and inflammatory condition, rheumatoid arthritis predominantly affects the hands, feet, other joints, as well as internal organs. Tofacitinib medicines work by restraining the activity of the Janus kinase enzymes that contribute to the inflammation, which results in rheumatoid arthritis symptoms. To illustrate, data from the National Arthritis Data Workgroup, a consortium of epidemiology experts in the United States, revealed in February 2022 that over 52.5 million American adults, constituting more than 22% of the population, have been diagnosed with arthritis or some other rheumatic ailment. The number of adults over 18 suffering from arthritis is estimated to hit 67 million by 2030. Thus, the rising incidence of rheumatoid arthritis is bolstering the expansion of the tofacitinib market.

Which Segments Are Detailed In The Global Tofacitinib Market Report?

The tofacitinib market covered in this report is segmented –

1) By Drug Class: Antirheumatic, Janus Kinase Inhibitor, Immunosuppressant

2) By Strength: 5mg, 10mg, 11mg, 22mg

3) By Route Of Administration: Oral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

5) By Application: Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Other Applications

Subsegments:

1) By Antirheumatic: Conventional Synthetic Antirheumatics, Targeted Synthetic Antirheumatics

2) By Janus Kinase Inhibitor: JAK1 Inhibitors, JAK2 Inhibitors, JAK3 Inhibitors

3) By Immunosuppressant: Corticosteroids, Non-Steroidal Immunosuppressants

Which Emerging Trends And Strategic Shifts Are Shaping The Tofacitinib Market?

The major players in the Stay-C-for-feed market are strategically uniting to increase product innovation, extend their market footprints, and advance animal health solutions. Such strategic partnerships imply the pooling of resources, skills, and efforts by two or more entities, with the aim to accomplish shared goals or objectives. For example, during February 2024, Cargill Incorporated, a US-based food company that supplies Stay-C for feed, collaborated with Enough, a manufacturer of mycoprotein-based food in the UK. From this partnership, Cargill procured stakes in Enough’s Series C funding round and entered into a business contract to use and market its Abunda mycoprotein. The mycoprotein, derived through a zero-waste fermentative procedure utilizing fungi and sugars derived sustainably from Cargill’s glucose syrup, is a wholesome food ingredient potent in amino acids and dietary fiber. This extended collaboration with Cargill will enable the joint creation of alternative protein-based foods and facilitate the increase in production throughout Europe and other regions.

Who Are The Key Contributors To Growth In The Tofacitinib Market?

Major companies operating in the tofacitinib market include Beacon Pharmaceuticals Limited, Pfizer Inc., Globe Pharmaceuticals Ltd., Drug International Limited, Dolphin Pharmaceuticals, Lancer Therapeutics, Glenmark Pharmaceuticals LTD., Sun Pharmaceutical Industries Ltd., Shandong Octagon Chemicals Limited, Zydus Lifesciences Ltd., Esteve Pharmaceuticals SA, Unichem Laboratories, Beijing Mesochem Technology Co. Ltd, Aprazer Healthcare Pvt Ltd, Apino Pharma Co Ltd, Delta Pharma Limited, Mediconlife, Sandoz International GmbH, Mylan N.V., Hetero Drugs Limited, Torrent Pharmaceuticals Ltd., Lupin Limited, Aurobindo Pharma Limited, Cipla Inc., Dr. Reddy’s Laboratories Ltd., Jubilant Life Sciences, Strides Pharma Science Limited, Alkem Laboratories Limited, Cadila Healthcare Limited, Wockhardt Limited, Alembic Pharmaceuticals Limited, Intas Pharmaceuticals Limited

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/tofacitinib-global-market-report

Which Region Is Projected To Lead The Tofacitinib Market By 2025?

North America was the largest region in the tofacitinib market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tofacitinib market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10779&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model